Novo Nordisk A/S (NYSE:NVO) Stock Price Down 6.1% - Here's Why

Key Points

• Novo Nordisk shares fell about 6.1% to roughly $44 despite better-than-expected second-quarter earnings and a narrowed outlook for 2026 sales and operating-profit declines.
• Investors remained concerned about softer-than-expected Wegovy pill momentum, fierce competition from Eli Lilly’s obesity drugs, and the impact of prior U.S. rebate effects on reported profit.
• The failed late-stage ZEUS trial for heart-drug candidate zilte...kimab increased worries about Novo Nordisk’s ability to diversify beyond GLP-1 medicines. Analysts maintain a consensus “Hold” rating with an average price target of $65.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares were down 6.1% on Tuesday . The company traded as low as $43.80 and last traded at $44.2390. 17,950,368 shares were traded during mid-day trading, a decline of 0% from the average daily volume of 17,988,822 shares. The stock had previously closed at $47.09.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q2 results exceeded expectations: Adjusted sales rose 7% at constant exchange rates to DKK 178.5 billion, while adjusted operating profit increased 11% to DKK 33.4 billion. Reported EPS of $0.96 surpassed the $0.77 consensus estimate. Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
• Positive Sentiment: Management raised its full-year outlook: Novo Nordisk narrowed the expected 2026 decline in adjusted sales and operating profit, citing GLP-1 volume growth, demand for the higher-dose Wegovy injection and favorable U.S. rebate adjustments. Novo Nordisk's Q2 profit beats forecasts, raises outlook
• Positive Sentiment: Oral Wegovy is gaining traction: The weight-loss pill has exceeded 5 million U.S. prescriptions since launch, supporting optimism that it can expand Novo Nordisk’s obesity-drug franchise. Novo Nordisk Q2 2026 earnings beat, raises full-year outlook
• Neutral Sentiment: Novo Nordisk is studying real-world GLP-1 users to assess potential thyroid-cancer risks. The update concerns an ongoing database study and does not establish a new safety signal. Novo Nordisk Probes Thyroid Cancer Risk in Real-World GLP-1 Users
• Negative Sentiment: Sales momentum disappointed relative to lofty expectations: Investors focused on softer-than-anticipated Wegovy pill sales, while reported operating profit declined because of prior-year U.S. rebate effects. Novo also faces intense competition from Eli Lilly’s Mounjaro and Zepbound. Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes
• Negative Sentiment: The failure of the late-stage ZEUS trial for heart drug candidate zilte...kimab weakened the case for diversifying beyond GLP-1 medicines and added to investor concerns about Novo Nordisk’s pipeline. Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Analysts Set New Price Targets

NVO has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. HSBC reissued a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a research note on Monday, July 13th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $65.56.

Novo Nordisk A/S Trading Down 6.2%

The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. The business has a fifty day simple moving average of $46.96 and a 200 day simple moving average of $45.32. The stock has a market cap of $197.18 billion, a price-to-earnings ratio of 10.37, a PEG ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion during the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVO. Arrowstreet Capital Limited Partnership acquired a new position in shares of Novo Nordisk A/S during the 1st quarter valued at about $287,660,000. Boston Partners acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $310,199,000. Price T Rowe Associates Inc. MD grew its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company's stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the period. Voloridge Investment Management LLC grew its holdings in Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company's stock valued at $244,594,000 after purchasing an additional 4,302,126 shares during the period. Finally, Maverick Capital Ltd. acquired a new position in Novo Nordisk A/S during the first quarter worth approximately $76,444,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source